NCT02110069 - A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

October 2, 2019

Study Completion Date

October 27, 2020

Conditions

Kaposiform Hemangioendothelioma (KHE)Kasabach-Merritt SyndromeTufted Angioma

Interventions

DRUG

Vincristine

Vincristine dose dependent upon weight. Weekly for 2 months (Induction); Weekly 2 months; every 2 weeks for next 5 months; every 3 weeks for 5 months (Maintenance)

DRUG

Sirolimus

Continuous dosing to maintain trough level of 10-15ng/ml.

Trial Locations (7)

21287

Johns Hopkins, Baltimore

30322

Emory Children's Healthcare of Atlanta, Atlanta

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

53226

Medical College of Wisconsin, Milwaukee

77094

Texas Children's Hospital, Houston

94304

Lucille Packard Children's Hospital Stanford, Palo Alto

02115

Boston Children's Hospital, Boston